Immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPh cytochrome P450 reductase in human superficial bladder tumours: Relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy

International Journal of Cancer

Volumn 109, Issue 5, 2004, Pages 703-709

  Basu, Saurajyoti ^a,c   Brown, John E ^b   Flannigan, G Michael ^c   Gill, Jason H ^a   Loadnian, Paul M ^a   Martin, Sandie W ^a   Naylor, Brian ^d   Scally, Andrew J ^a   Seargent, Jill M ^a   Shah, Tariq ^c   Puri, Rajiv ^c   Phillips, Roger M ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

^b KINGSTON UNIVERSITY   (United Kingdom)

^c ST LUKE S HOSPITAL   (United Kingdom)

^d BRADFORD ROYAL INFIRMARY   (United Kingdom)

Author keywords

Bladder cancer; Cytochrome P450 reductase; Mitomycin C; NQO1

Indexed keywords

CYTOCHROME P450 REDUCTASE; MITOMYCIN C; PROTEIN; PROTEIN NQO1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; UNCLASSIFIED DRUG;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER TUMOR; CANCER PATIENT; CANCER RESEARCH; CLINICAL ARTICLE; DNA DAMAGE; DRUG EFFECT; ENZYME ANALYSIS; ENZYME SPECIFICITY; ENZYMOLOGY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR RECURRENCE;

ADMINISTRATION, INTRAVESICAL; ANTIBIOTICS, ANTINEOPLASTIC; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MITOMYCIN; NAD(P)H DEHYDROGENASE (QUINONE); NADPH-FERRIHEMOPROTEIN REDUCTASE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 12144287215     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20005     Document Type: Article

References (47)

1. McLeod HL, Murray GI, Mollison J, McKay J, Cassidy J. Selection of markers to predict tumour response or survival: description of a novel approach. Eur J Cancer 1999;35:1650-2.
2. van't Veer LJ, Dai HY, van de Vijver MJ, He YDD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
3. Workman P, Walton MI. Enzyme directed bioreductive drug development. In: Adams GE, Breccia A, Fielden EM, Workman P, eds. Selective activation of drugs by redox processes. New York: Plenum Publishing Corp., 1990. 173-191.
4. Sartorelli AC, Hodnick WF, Belcourt MF, Tomaz M, Haffty B, Fisher JJ, Rockwell S. Mitomycin C: a prototype bioreductive agent. Oncol Res 1994;6:501-8.
5. Ross D, Beall HD, Siegel D, Traver RD, Gustafson DL. Enzymology of bioreductive drug activation. Br J Cancer 1996;74:S1-8.
6. Cummings J, Spanswick VJ, Tomaz M, Smyth JF. Enzymology of Mitomycin C metabolic activation in tumour tissue: implications for enzyme directed bioreductive drug development. Biochem Pharmacol 1998;56:405-14.
7. Spanswick VJ, Cummings J, Smyth JF. Current issues in the enzymology of mitomycin C metabolic activation. Gen Pharmacol 1998; 31:539-44.
8. Workman P. Enzyme directed bioreductive drug development revisited: a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolising enzymes, particularly DT-diaphorase. Oncol Res 1994;6:461-75.
9. Krishna MC, DeGraff W, Tamura S, Gonzalez FJ, Samuni A, Russo A, Mitchell JB. Mechanism of hypoxic and aerobic toxicity of mitomycin Cin Chinese hamster V79 cells. Cancer Res 1991;51:6622-8.
10. Malkinson AM, Siegel D, Forrest GL, Gazdar AF, Oie HK, Chan DC, Bunn PA, Mabry M, Dykes DJ, Harrison SD Jr, Ross D. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: relationship to the response of lung tumour xenografts to mitomycin C. Cancer Res 1992;52:4752-7.
11. Robertson N, Stratford IJ, Houlbrook S, Carmichael J, Adams GE. The sensitivity of human tumour cells to quinone bioreductive drugs: what role for DT-diaphorase? Biochem Pharmacol 1992;44:409-12.
12. Nishiyama M, Saeki S, Aogi K, Hirabayashi N, Toge T. Relevance of DT-diaphorase activity to Mitomycin C (MMC) efficacy on human cancer cells: differences in in vitro and in vivo systems. Int J Cancer 1993;53:1013-6.
13. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R, Lewis AD. Reductase enzyme expression across the National Cancer lnstitute tumour cell line panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 1996;88:259-69.
14. Mikami K, Naito M, Tomida A, Yamada M, Sirakusa T, Tsuruo T. DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric cell lines. Cancer Res 1996;56:2823-6.
15. Phillips RM, Burger A, Loadman PM, Jarrett CM, Swaine DJ, Fiebig HH. Predicting tumour response to Mitomycin C on the basis of DT-diaphorase activity or drug metabolism by tumour homogenates: implications for enzyme directed bioreductive drug development. Cancer Res 2000;60:6384-90.
16. Sharp SY, Kelland LR, Valenti MR, Brunton LA, Hobbs S, Workman, P. Establishment of an isogenic human colon tumour model for NQO1 gene expression: Application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo. Mol Pharmacol 2000;58:1146-55.
17. Belcourt MF, Hodnick WF, Rockwell S, Sartorelli AC. Differential toxicity of mitomycin C and porfiromycin to aerobic and hypoxic chinese hamster ovary cells overexpressing human NADPH:cytochrome P-450 reductase. Proc Natl Acad Sci U S A 1996;93:456-60.
18. Gan Y, Mo Y, Kalns JE, Lu J, Danenberg K, Danenberg P, Wientjes MG, Au JL-S. Expression of DT-diaphorase and cytochrome P450 reductase correlates with Mitomycin C activity in human bladder tumours. Clin Cancer Res 2001;7:1313-9.
19. Schmittgen TD, Weaver JM, Badalament RA, Wientjes MG, Klein EA, Young DC, Au JL-S. Correlation of human bladder tumour histoculture proliferation and sensitivity to mitomycin C with tumour pathology. J Urol 1994;152:1632-6.
20. Kubota T, Sasano N, Abe O, Nakao I, Kawamura E, Saito T, Endo M, Kimura K, Hiroshi D, Sasano H, Nagura H, Ogawa N, Hoffman RM and the chemosensitivity study group for the histoculture drug response assay. Potential of the histoculture drug response assay to contribute to cancer patient survival. Clin Cancer Res 1995;1:1537-43.
21. Furukawa T, Kubota T, Hoffman RM. The clinical application of the histoculture drug response assay. Clin Cancer Res 1995;1:305-11.
22. Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Meijden A, Parmar MK, Bijnens L. A combined analysis of European Organization for Research and Treatment of Cancer. and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 1996;156:1934-40.
23. Siegel D, Franklin WA, Ross D. Immunohistochemical detection of NAD(P)H:Quinone oxidoreductase in human lung and lung tumours. Clin Cancer Res 1998;4:2065-70.
24. Choudry GA, Hamilton Stewart PA, Double JA, Krul MRL, Naylor B, Flannigan GM, Shah TK, Brown JE, Phillips RM. A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase. EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9. Br J Cancer 2001;85:1137-46.
25. Li D, Gan Y, Wientjes MG, Badalament RA, Au JL-S. Distribution of DT-diaphorase and reduced nicotinamide adenine dinucleotide phosphate: cytochrome P450 oxidoreductase in bladder tissue and tumours. J Urol 2001;166:2500-5.
26. López de Cerain A, Marín A, Idoate MA, Tuñón MT, Bello J. Carbonyl reductase and NADPH cytochrome P450 reductase activities in human tumoural and normal tissues. Eur J Cancer 1999;35:320-4.
27. Schlager JJ, Powis G. Mitomycin C is not metabolised by but is an inhibitor of human kidney NAD(P)H:(Quinone acceptor) oxidoreductase. Cancer Chemother Pharmacol 1988;22:126-30.
28. Workman P, Walton MI, Powis G, Schlager JJ. DT-diaphorase: questionable role in mitomycin C resistance, but a target for novel bioreductive drugs? Br J Cancer 1989;60:800-2.
29. Siegel D, Beall HD, Kasai M, Arai H, Gibson NW, Ross D. PH dependent inactivation of DT-diaphorase by mitomycin C and porfiromycin. Mol Pharmacol 1993;44:1128-34.
30. Griffiths JJ. Are cancer cells acidic? Br J Cancer 1991;64:425-7.
31. Pan S, Andrews PA, Glover CJ, Bachur NR. Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase. J Biol Chem 1984;259:959-66.
32. Gustafson DL, Pritsos CA. Bioactivation of mitomycin C by xanthine dehydrogenase from EMT6 mouse mammary carcinoma tumours. J Natl Cancer Inst 1992;84:1180-5.
33. Hodnick WF, Sartorelli AC. Reductive activation of mitomycin C by NADH: cytochrome b5 reductase. Cancer Res 1993;53:7483-9.
34. Spanswick VJ, Cummings J, Smyth JF. Enzymology of mitomycin c activation in tumour tissue. Characterisation of a novel mitochondrial reductase. Biochem Pharmacol 1996;51:1623-30.
35. Prieto-Alamo MJ, Laval F. Overexpression of the human HAP1 protein sensitizes cells to the lethal effect of bioreductive drugs. Carcinogenesis 1999;20:415-9.
36. Matsuda H, Kimura S, Iyanagi T. One-electron reduction of quinones by the neuronal nitric-oxide synthase reductase domain. Biochim Biophys Acta 2000;1459:106-16.
37. Pan S-S, Yu F, Hipsher C. Enzymatic and pH modulation of mitomycin C induced DNA damage in mitomycin C resistant HCT 116 human colon cancer cells. Mol Pharmacol 1993;43:870-7.
38. Plumb JA, Workman P. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon tumour cell line that lacks DT-diaphorase activity. Int J Cancer 1994;56:134-9.
39. Kharbanda S, Yuan Z-M, Taneja N, Weichselbaum R, Kufe D. p56/p53lyn tyrosine kinase activation in mammalian cells treated with mitomycin C. Oncogene 1994;9:3005-11.
40. Sun X, Ross D. Quinone induced apoptosis in human colon adenocarcinoma cells via DT-diaphorase mediated bioactivation. Chem Biol Interact 1996;100:267-76.
41. Muscarella DE, Bloom SE. Involvement of gene specific DNA damage and apoptosis in the differential toxicity of mitomycin C analogs towards B lineage versus T lineage lymphoma cells. Biochem Pharmacol 1997;53:811-22.
42. Belcourt MF, Penketh PG, Hodnick WF, Johnson DA, Sherman DH, Rockwell S, Sartorelli AC. Mitomycin resistance in mammalian cells expressing the bacterial mitomycin C resistance protein MCRA. Proc Natl Acad Sci U S A 1999;96:10489-94.
43. Baumann RP, Hodnick WF, Seow HA, Belcourt MF, Rockwell S, Sherman DH, Sartorelli AC. Reversal of mitomycin C resistance by overexpression of bioreductive enzymes in Chinese hamster ovary cells. Cancer Res 2001;61:7770-6.
44. Kelly JD, Williamson KE, Weir HP, McManus DT, Hamilton PW, Keasne PF, Johnston SR. Induction of apoptosis by mitomycin C in an ex vivo model of bladder cancer. Br J Urology International 2000;85: 911-7.
45. Asher G, Lotem J, Kama R, Sachs L, Shaul Y. NQO1 stabilises p53 through a distinct pathway. Proc Natl Acad Sci U S A 2002;99:3099-104.
46. Asher G, Lotem J, Sachs L, Kahana C, Shaul Y. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1. Proc Natl Acad Sci U S A 2002;99:13125-30.
47. Borden Jr LS, Clark PE, Hall MC. Bladder Cancer. Current Opin Oncol 2003;15, 227-33.